MelliCell is developing industrial-scale technology for drug development in mature human fat cells aimed at transforming obesity treatment. The company’s core work focuses on leveraging cellular-level insights from mature adipocytes to identify therapeutic opportunities that could improve patient outcomes. The recently awarded NSF SBIR project supports R&D to scale this technology for industrial use. MelliCell received a $275,000 Phase I SBIR grant from the U.S. National Science Foundation to conduct the work described. If successful, the project would position the company to apply for Phase II funding and supplements through America's Seed Fund, potentially totaling up to $2 million. Prince Nnah is CEO/Founder and the company is based in Newton, Massachusetts. MelliCell uses proprietary technology to recreate human fat cells and test therapies aimed at reversing obesity and type 2 diabetes. The company was founded in 2020 and describes itself as being in early funding stages. It recently closed a pre-seed round that included Kensington Capital and other angel investors and is planning a Series Seed in the third quarter. MelliCell appointed Todd Zion, Ph.D., founder of SmartCells and CEO of Akston Biosciences, to its advisory board to add diabetes and bioscience expertise. CEO Prince Nnah said the company is pursuing investment and partnership opportunities to advance therapeutics. The company is based in Newton, Mass.

Total raised

$0M

Funding rounds

2

Latest round

Grant

Latest activity

Mar 2024